SCHEMBL5775730

SCHEMBL5775730

COC1CN(Cc2cccc3c2CCN(C(=O)O)C3)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ ATM Q13315 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ ABHD6 Q9BV23 5/20 0.39
▸ CHRM2 P08172 1/20 0.38
▸ CHRM4 P08173 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ CHRM3 P20309 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ CPT2 P23786 1/20 0.37
▸ CPT1A P50416 1/20 0.37
▸ CD274 Q9NZQ7 3/20 0.37
▸ PDCD1 Q15116 2/20 0.37
▸ NAMPT P43490 1/20 0.36
▸ PTGER4 P35408 1/20 0.36
▸ PTGER2 P43116 1/20 0.36
▸ PDCD1LG2 Q9BQ51 1/20 0.36
▸ GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5774994 0.85 KDM4E (0.41) KDM4ETDP1ATML3MBTL1ABHD6
SCHEMBL5777006 0.82 SMN1; SMN2 (0.44) KDM4EABHD6MEN1KMT2ANAMPT
SCHEMBL5776465 0.79 CYP2A13 (0.44) KDM4EL3MBTL1NAMPT
SCHEMBL18584701 0.76 ABHD6 (0.43) KDM4EABHD6MEN1KMT2AGAA
SCHEMBL22366387 0.75 S1PR5 (0.42) ABHD6CPT2CPT1APTGER4PTGER2
SCHEMBL28901639 0.75 ABHD6 (0.41) KDM4EABHD6MEN1KMT2AGAA
SCHEMBL16268894 0.75 S1PR5 (0.40) KDM4EABHD6MEN1KMT2AGAA
SCHEMBL6279147 0.74 ALDH1A1 (0.44) KDM4ETDP1ABHD6MEN1KMT2A
SCHEMBL28245902 0.73 S1PR5 (0.51) KDM4ETDP1L3MBTL1ABHD6MEN1
SCHEMBL6287145 0.72 KDM4E (0.40) KDM4EABHD6MEN1KMT2ACPT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1483257-B1 QUINAZOLINE COMPOUNDS USEFUL IN THERAPY PFIZER LTD (GB) 2006-09-13 — — EP disclosed
US-6936619-B2 Cardiovascular disorders; antilipemic agents; sexual disorders PFIZER, INC. (US) 2005-08-30 — — US disclosed
EP-1483257-A1 QUINAZOLINE COMPOUNDS USEFUL IN THERAPY Pfizer Limited (GB) 2004-12-08 — — EP disclosed
US-20040029859-A1 Compounds useful in therapy PFIZER INC. 2004-02-12 — — US disclosed
WO-2003076427-A1 QUINAZOLINE COMPOUNDS USEFUL IN THERAPY PFIZER LIMITED (GB) 2003-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029859-A1 Compounds useful in therapy ADRA1D, HSD3B1, PTGER1 KDM4E 2413/4885TDP1 1558/4885ATM 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback